A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients.
Moreno G, Ruiz-Botella M, Martín-Loeches I, Gómez Álvarez J, Jiménez Herrera M, Bodí M, Armestar F, Marques Parra A, Estella Á, Trefler S, Jorge García R, Murcia Paya J, Vidal Cortes P, Díaz E, Ferrer R, Albaya-Moreno A, Socias-Crespi L, Bonell Goytisolo JM, Sancho Chinesta S, Loza A, Forcelledo Espina L, Pozo Laderas JC, deAlba-Aparicio M, Sánchez Montori L, Vallverdú Perapoch I, Hidalgo V, Fraile Gutiérrez V, Casamitjana Ortega AM, Martín Serrano F, Nieto M, Blasco Cortes M, Marín-Corral J, Solé-Violán J, Rodríguez A; on behalf COVID-19 SEMICYUC Working Group.
Moreno G, et al.
Med Intensiva. 2023 Jan;47(1):23-33. doi: 10.1016/j.medin.2021.10.002. Epub 2021 Oct 26.
Med Intensiva. 2023.
PMID: 34720310
Free PMC article.